A genetic study of two calcium-independent cytosolic PLA2 genes in schizophrenia

Stevens, 1972, The distribution of phospholipid fractions in the red cell membrane of schizophrenics, Schizophr. Bull., 6, 60, 10.1093/schbul/1.6.60 Tolbert, 1983, Defects in transmethylation and membrane lipids in schizophrenia, Psychopharmacol. Bull., 19, 594 Hitzemann, 1984, Membrane abnormalities in the psychoses and affective disorders, J. Psychiatr. Res., 18, 319, 10.1016/0022-3956(84)90022-0 Pettegrew, 1991, Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy, Arch. Gen. Psychiatry, 48, 563, 10.1001/archpsyc.1991.01810300075011 Fujimoto, 1992, Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging, Acta Psychiatr. Scand., 86, 455, 10.1111/j.1600-0447.1992.tb03297.x Keshavan, 1993, Erythrocyte membrane phospholipids in psychotic patients, Psychiatr. Res., 59, 89, 10.1016/0165-1781(93)90032-C Glen, 1994, A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases, Schizophr. Res., 12, 53, 10.1016/0920-9964(94)90084-1 Stanley, 1994, Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study, Schizophr. Res., 13, 209, 10.1016/0920-9964(94)90044-2 Stanley, 1995, An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy, Arch. Gen. Psychiatry, 52, 399, 10.1001/archpsyc.1995.03950170073010 Potwarka, 1999, A 1H-decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls, Biol. Psychiatry, 45, 687, 10.1016/S0006-3223(98)00136-X Doris, 1998, Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia, Schizophr. Res., 31, 185, 10.1016/S0920-9964(98)00016-4 Khan, 2002, Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics, Schizophr. Res., 58, 1, 10.1016/S0920-9964(01)00334-6 Arvindakshan, 2003, Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients, Biol. Psychiatry, 53, 56, 10.1016/S0006-3223(02)01443-9 Dennis, 1994, Diversity of group types, regulation, and function of phospholipase A2, J. Biol. Chem., 269, 13057, 10.1016/S0021-9258(17)36794-7 Gattaz, 1987, Increased plasma phospholipase A2 activity in schizophrenic patients: reduction after neuroleptic therapy, Biol. Psychiatry, 22, 421, 10.1016/0006-3223(87)90164-8 Gattaz, 1990, Increased serum phospholipase A2 activity in schizophrenia: a replication study, Biol. Psychiatry, 28, 495 Noponen, 1993, Elevated PLA2 activity in schizophrenics and other psychiatric patients, Biol. Psychiatry, 34, 641, 10.1016/0006-3223(93)90157-9 Gattaz, 1995, Increased platelet phospholipase A2 activity in schizophrenia, Schizophr. Res., 16, 1, 10.1016/0920-9964(94)00060-L Albers, 1993, Phospholipase A2 activity in serum of neuroleptic-naïve psychiatric inpatients, Pharmacopsychiatry, 26, 94, 10.1055/s-2007-1014349 Ross, 1997, Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2, Arch. Gen. Psychiatry, 54, 487, 10.1001/archpsyc.1997.01830170113015 Ross, 1999, Differential alteration of phospholopase A2 activities in brain of patients with schizophrenia, Brain Res, 821, 407, 10.1016/S0006-8993(99)01123-3 Hudson, 1996, Genetic vairiant near cytosolic phospholipase A2 associated with schizophrenia, Schizophr. Res., 21, 111, 10.1016/0920-9964(96)00031-X M. Peet, C.N. Ramchand, J. Lee, et al., Association of the Ban I dimorphic site at the human cytosolic phospholipase A2 gene with schizophrenia, Psychiatr. Genet. 8 (998) 191–192. Wei, 1998, Is the cPLA2 gene associated with schizophrenia?, Mol. Psychiatry, 3, 480, 10.1038/sj.mp.4000445 Wei, 2004, A study of a genetic association between the PTGS2/PLA2G4A locus and schizophrenia, Prostaglandins Leukot. Essent. Fatty Acids, 70, 413, 10.1016/j.plefa.2003.12.018 Rybakowski, 2003, The study of cytosolic phospholipase A2 gene polymorphism in schizophrenia using eye movement disturbances as an endophenotypic marker, Neuropsychobiology, 47, 115, 10.1159/000070578 Pae, 2004, BanI polymorphism of the cytosolic phospholipase A2 gene may confer susceptibility to the development of schizophrenia, Prog. Neuropsychopharmacol. Biol. Psychiatry, 28, 739, 10.1016/j.pnpbp.2004.05.009 Price, 1997, Lack of association between schizophrenia and a polymorphism close to the cytosolic phospholipase A2 gene, Psychiatr. Genet., 7, 111, 10.1097/00041444-199723000-00004 Chowdari, 2001, Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples, Psychiatr. Genet., 111, 207, 10.1097/00041444-200112000-00005 Frieboes, 2001, Lack of association between schizophrenia and the phospholipase-A (2) genes cPLA2 and sPLA2, Am. J. Med. Genet., 105, 246, 10.1002/ajmg.1262 Yu, 2004, No association between the PTGS2/PLA2G4A locus and schizophrenia in a Chinese population, Prostaglandins Leukot. Essent. Fatty Acids, 71, 405, 10.1016/j.plefa.2004.09.001 Tao, 2005, The cytosolic PLA2 genes possibly contribute to the etiology of schizophrenia, Am. J. Med Genet., 137B, 56, 10.1002/ajmg.b.30210 Emsley, 2003, Clinical potential of omega-3 fatty acids in the treatment of schizophrenia, CNS Drugs, 17, 1081, 10.2165/00023210-200317150-00003 Peet, 2003, Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results, Prostaglandins Leukot. Essent. Fatty Acids, 69, 477, 10.1016/j.plefa.2003.08.020